Cooley M&A

OCTOBER 19, 2022

Some of the tax provisions contained in the legislation, including the 1% excise tax on certain stock buybacks, may impact special purpose acquisition companies (SPACs) at key points in their life cycle. Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals. TCGplayer Agrees to Sell to eBay.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

M&A Leadership Council

AUGUST 15, 2022

For example, in Switzerland, Sandoz and Ciba spun off their chemicals business units – one as a taxable initial public offering and one as a tax-free “demerger” – before merging their pharmaceutical cores into Novartis. Sometimes spin-offs precede mergers.

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

Cooley M&A

JANUARY 30, 2024

Activist target profile: Top flags for tech and healthcare companies Activists are stock pickers – generally building a position at a target company only if they can drive meaningful risk-adjusted returns. Campaigns aimed at selling companies tend to be waged by existing stockholders, some of whom may be first time activists.

Private Equity 52

Private Equity M&A Investors Capital 52